Navigation Links
ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
Date:10/22/2010

EXTON, Pa., Oct. 22 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding Cinryze™ (C1 Esterase Inhibitor [Human]) industrial scale manufacturing expansion activities. The FDA has requested additional information related to observations from the pre-approval inspection and review of the technical processes.  

"We and our partner Sanquin will begin working immediately to respond to the FDA as expeditiously as possible," said Vincent Milano, ViroPharma's president and chief executive officer.  "And, we plan to commence manufacturing industrial scale lots at risk in the first quarter of 2011."  

Continued Milano, "We remain committed to provide patients with an uninterrupted supply of Cinryze.  In addition to our efforts around our industrial scale, we expect our currently approved manufacturing process alone will yield up to 60,000 doses annually."

Conference Call and Webcast

ViroPharma is hosting a brief live teleconference and webcast with senior management on October 22, 2010 at 11:00 a.m. Eastern. To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international).  After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.  

Alternatively, the live webcast of the conference call can be accessed via ViroPharma's website at http://www.viropharma.com.  Windows Media or Real Player will be needed to access the webcast.  An audio archive will be available at the same address until November 5, 2010.

About Cinryze™ (C1 esterase inhibitor [human])

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  UBM Medica US ... leading online community for medical imaging professionals, presents special ... for Medical Imaging Management,s 2014 Annual Meeting . ... coverage: , 11 Principles of Successful ... lead to greater profitability. , Why Don,t ...
(Date:8/27/2014)... 2014 /PRNewswire-iReach/ -- "Fatty Liver Disease Global Clinical Trials ... Disease clinical trial scenario. This report provides elemental information ... Fatty Liver Disease . It includes an overview of ... the site of trial conduction across the globe. The ... by their phase, trial status, prominence of the sponsors ...
(Date:8/27/2014)... CITY, Calif. , Aug. 27, 2014 /PRNewswire-iReach/ ... emergency response system design, blended emergency medical training ... CPR/AED (automated external defibrillator) training from the ... the Army Reserve 81 st Regional ... Security and Investigations contract includes nationwide CPR/AED/First Aid ...
Breaking Medicine Technology:Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 2Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 3Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 2Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 3Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 4Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 5Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 2Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 3
... ... ... - SORT OUT III Data Presented at American College of Cardiology Meeting,in Atlanta and Published in the Lancet , ... , , ...
... Md. , March 17 Micromet, Inc. (Nasdaq: MITI ) announced today the closing of its previously ... shares of common stock. As a result, Micromet sold a total of 11.5 million shares of its common stock at ... ... , , ...
Cached Medicine Technology:Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 2Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 3Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 4Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 5Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 6Micromet Closes $80.5 Million Public Offering of Common Stock 2Micromet Closes $80.5 Million Public Offering of Common Stock 3Micromet Closes $80.5 Million Public Offering of Common Stock 4
(Date:8/27/2014)... 27, 2014 With most forms ... sense to use hearing protection when exposed to ... are many different forms of hearing protection ... provide hearing protection training and devices for workers ... industries. The National Institute of Occupational Safety and ...
(Date:8/27/2014)... time you experienced worrisome medical symptoms, did you ... professional? If so, you,re not alone. Consumers are ... support groups to gather anecdotal information and advice, ... trustworthy sources. New research to be presented at ... the characteristics of consumers who use the Internet ...
(Date:8/27/2014)... 27, 2014 (HealthDay News) -- A new genetic discovery ... fight the bowel disorder, researchers report. The ... affect how their genes work, and said these changes ... raising the possibility of a simple diagnostic test for ... disease develops and suggest possible gene targets for new ...
(Date:8/27/2014)... An experimental drug designed to help regulate the blood,s iron ... of inflammation, according to results from the first human ... Blood , the Journal of the American ... occurs when red blood cells are in short supply or ... body does not get enough oxygen, since there are fewer ...
(Date:8/27/2014)... 8/27/14)Dartmouth cancer researchers developed and tested an advanced ... interactions that contribute to disease as published yesterday ... The approach fills a gap in current analyses. ... interactions among genetic and environmental factors. When many ... versus those that reflect chance combinations among affected ...
Breaking Medicine News(10 mins):Health News:Hearing Health Solutions Now Offering a Full Line of Occupation Hearing Protection Services and Expanded Line of Ear Protection Products 2Health News:Hearing Health Solutions Now Offering a Full Line of Occupation Hearing Protection Services and Expanded Line of Ear Protection Products 3Health News:Educated consumers more likely to use potentially unreliable online healthcare information 2Health News:Scientists Spot Genetic Clues to Crohn's Disease 2Health News:Drug represents first potential treatment for common anemia 2Health News:Dartmouth isolates environmental influences in genome-wide association studies 2
... 7-day old baby was charred to death due to a short ... their joy and hopes. The incubator in which the baby was ... incident had happened due to negligence of the hospital staff while ... were saved due to prompt action of the medical staff who ...
... The doctor, who had dismissed increased risk of heart attack ... that his views are 'out of the mainstream' as it ... company, Merck and Co. ,Thomas Cona and John ... the drug had resulted in heart attacks. More than 10, ...
... of the biggest problems worldwide. There is an urgent ... these new antibiotic resistant infections. // Researchers at ... say they have used natural bacteria living in soil ... discovery would allow scientists race ahead in developing antibiotics ...
... behind the alleged leak of question papers of the MD/MS ... India Institute of Medical Sciences (AIIMS), // has been ... Madurai Medical College. ,Satish Kumar (26),an MD (Paediatric) ... and two other doctors have been taken into custody ...
... (PTSD) is a disabiling anxiety disorder, which was first ... War I, as soldier's heart and shell shock respectively. ... are affected by cancer and their families as well ... affects about 10 percent of those exposed to extreme ...
... shared between India and China. The world's fastest growing ... to tackle the // problem of this latest threat. , ... Du Qinglin met and discussed management of avian influenza ... was agreed that exchange of information and technical cooperation between ...
Cached Medicine News:Health News:The Face Of Indian Health Care: A World Health Day Evaluation 2Health News:The Face Of Indian Health Care: A World Health Day Evaluation 3Health News:The Face Of Indian Health Care: A World Health Day Evaluation 4Health News:Doctor Grilled In Court For False Report About Vioxx Health Risk 2Health News:New Therapy For Treating Post-Traumatic Stress Syndrome 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: